Abstract: The present invention relates to a pharmaceutical composition and method for treating and preventing musculoskeletal and connective tissue diseases of unknown etiology, such as different forms of arthritis and other rheumatic conditions, comprising a combination of therapeutic agents that improve the processes of blood circulation and angiogenesis in the affected tissues, as well as other supporting therapies. Among the components of herein proposed pharmaceutical composition, are: vitamin K, polyunsaturated fatty acids (blood thinner), and niacin (vasodilator and hypolipidemic agent).

Abstract: The present invention relates to a pharmaceutical composition and method for treating and preventing musculoskeletal and connective tissue diseases of unknown etiology, such as different forms of arthritis and other rheumatic conditions, comprising a combination of therapeutic agents that improve the processes of blood circulation and angiogenesis in the affected tissues, as well as other supporting therapies. Among the components of herein proposed pharmaceutical composition, are: vitamin K, polyunsaturated fatty acids (blood thinner), and niacin (vasodilator and hypolipidemic agent).

Abstract: A DNA vector is provided for stable insertion and expression of heterologous genes in the plastid genomes of any Angiosperm plant cell. In this vector, foreign genes can be inserted in multiple cloning sites located at an artificial intergenic region obtained from the combination of atpB and rbcL operons that belong to plants of different Classes (dicotyledonous and monocotyledonous). The expression cassette is inserted into the plastid genome by homologous recombination between the atpB and rbcL border sequences of the vector with the corresponding homologous regions of plastid genome; in such a way that more than one gene of interest can be expressed under the transcriptional control of the rbcL promoter adjacent to the border region that encodes for the atpB gene.

Abstract: Extracellular fructosyltransferase of Acetobacter diazotrophicus was isolated and purified and its enzymatic properties were established. Cloning, sequencing and genetic manipulation of the fructosyltransferase gene so as to produce high levels of the enzyme in recombinant prokaryotic and eukaryotic cells. Both natural and recombinant fructosyltransferase of Acetobacter diazotrophicus produce fructose-containing oligosaccharides and fructans. The enzyme yields in particular high levels of fructooligosaccharides from sucrose, such as kestose and kestotetraose which can be used as natural low-calorie sweeteners.

Abstract: Extracellular fructosyltransferase of Acetobacter diazotrophicus was isolated and purified and its enzymatic properties were established. Cloning, sequencing and genetic manipulation of the fructosyltransferase gene so as to produce high levels of the enzyme in recombinant prokaryotic and eukaryotic cells. Both natural and recombinant fructosyltransferase of Acetobacter diazotrophicus produce fructose-containing oligosaccharides and fructans. The enzyme yields in particular high levels of fructooligosaccharides from sucrose, such as kestose and kestotetraose which can be used as natural low-calorie sweeteners.